Who Owns Black Diamond Therapeutics Stock?
NASDAQ: BDTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 72.58%
- Held by insiders
- 0.66%
- Institutional holders
- 139
- Institutions 72.6%
- Insiders 0.7%
- Public and other 26.8%
Who owns Black Diamond Therapeutics stock?
Institutional investors own about 72.6% of Black Diamond Therapeutics's shares, spread across 139 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.66% of BDTX.
The largest institutional holders are NEA Management Company, LLC (7.74%), T. Rowe Price Investment Management, Inc. (7.01%) and Blackrock Inc. (6.82%). Together, the top 10 institutions control 42.1% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their BDTX positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BDTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| NEA Management Company, LLC | 4.45M | 7.74% | 0.0% |
| T. Rowe Price Investment Management, Inc. | 4.03M | 7.01% | -61.9% |
| Blackrock Inc. | 3.92M | 6.82% | +253.9% |
| Acadian Asset Management. LLC | 2.35M | 4.09% | 0.0% |
| Vanguard Capital Management LLC | 2.13M | 3.70% | +14.8% |
| Renaissance Technologies, LLC | 1.96M | 3.42% | +19.4% |
| Defilade Capital Management, L.P. | 1.67M | 2.92% | +100.0% |
| Dimensional Fund Advisors LP | 1.37M | 2.38% | +4.9% |
| Geode Capital Management, LLC | 1.22M | 2.12% | +127.0% |
| Connor Clark & Lunn Investment Management Ltd | 1.09M | 1.90% | +3.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BDTX
| Fund | Shares | % Held |
|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. | 2.12M | 3.69% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.56M | 2.71% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 1.35M | 2.36% |
| iShares Trust-iShares Russell 2000 ETF | 1.19M | 2.07% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 599.39K | 1.04% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 513.12K | 0.89% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 511.25K | 0.89% |
| iShares Trust-iShares U.S. Small-Cap Equity Factor ETF | 478.58K | 0.83% |
| iShares Trust-iShares Russell 2000 Value ETF | 460.69K | 0.80% |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 375.00K | 0.65% |
Frequently asked questions
Who is the largest shareholder of Black Diamond Therapeutics?
NEA Management Company, LLC is the largest institutional shareholder of BDTX, owning 7.74% of shares outstanding (4.45M shares) as of its latest 13F filing.
What percentage of Black Diamond Therapeutics is owned by institutions?
Institutions own about 72.6% of BDTX shares and 73.1% of the public float.
How much of Black Diamond Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.66% of BDTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.